Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2024 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
November 06, 2023 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference...
November 02, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
October 31, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
September 05, 2023 07:00 ET | Source: MacroGenics, Inc.

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
August 31, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
August 09, 2023 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50...
July 31, 2023 17:35 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
May 09, 2023 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipelineMultiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC)Cash runway through...
May 04, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...